International Clinical Registry for Patients with Rare Embryonal or Sarcomatous Tumors of the Central Nervous System within the German Society for Pediatric Oncology and Hematology

Rare embryonic and sarcomatous brain tumors are among the aggressive cancers of the central nervous system (CNS) that most often occur in childhood. They differ from tumors such as medulloblastoma in that they have only recently been able to be definitively identified, and only with the help of modern molecular genetic methods. These tumors arise from genetic changes in the cells of the nervous system, causing cells to divide uncontrollably and develop into malignant tumors. Embryonic tumors arise from very immature cells that form during early brain development and can later transform into cancer cells. Sarcomatous tumors, on the other hand, originate from connective or supporting tissue (e.g., muscle or connective tissue cells) and can occur in the brain when such cells become malignant there. Since these types of tumors are very rare, there is currently little experience regarding the best possible treatment strategies. Treatment typically consists of a combination of various approaches, such as surgery, chemotherapy, and radiation therapy. The CNS-InterREST GPOH registry (International Clinical Registry for Rare Embryonal and Sarcomatous CNS Tumors) is sponsored and coordinated by the German Society for Pediatric Oncology and Hematology (GPOH).

The goal of this registry study is to create a shared database that consolidates clinical, molecular genetic, and imaging data. No new medications are being tested; rather, existing information is being collected. This information is intended to help improve diagnosis, plan treatments more effectively, and facilitate future international studies. Physicians in Germany can enroll children and adolescents in the registry if there is a suspected or confirmed diagnosis of one of these rare tumors. All data will be treated confidentially and stored in anonymized form. Researchers who submit a reviewed application may use the data to further deepen our understanding of these rare diseases.

Children and adolescents up to age 18 with a confirmed diagnosis of a rare embryonal or sarcomatous CNS tumor are eligible to participate. Consent must be obtained from the patients and/or their legal guardians, depending on the patient’s age and cognitive development.